Company
Everlab
Runs a preventive health screening and diagnostics service for individual paying members. A single intake bundles whole-body MRI, CT coronary angiography, DEXA body composition and bone density, VO2 max and isometric strength testing, ECG, continuous glucose monitoring and blood panels covering more than 100 biomarkers across cardiovascular, metabolic, hormonal, inflammatory, toxicological and performance domains. Results are pulled into one record alongside clinician review, specialist referral, prescriptions and wearable data, with the stated aim of catching disease risk earlier than standard primary care. Pricing is tiered, from A$499 for a blood biomarker package to A$2,999 a year for the full programme. The longevity relevance is screening and early detection, not any therapeutic or ageing-modifying intervention: the company sells testing and care coordination, and no published outcome data establishing that its screening extends life or reduces mortality was found in the sources reviewed.
At a glance
- Listing
- Private, not listed
- Category
- Diagnostics
- Headquarters
- Melbourne, Victoria, Australia
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- Diagnostics
- Market
- Australia
- Recent inflection
- Raised a A$65m Series A led by Airtree Ventures, announced 17 June 2026, with Plural, Left Lane Capital, b2venture and cricketer Pat Cummins participating. It came less than twelve months after a US$10m (A$15m) seed led by Left Lane Capital reported 24 July 2025, when the company cited a waitlist in the tens of thousands and planned international expansion (SmartCompany, 17 June 2026; Longevity.Technology, 24 July 2025).
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | Unlisted |
| Ticker | None |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Private |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Melbourne, Victoria, Australia
- Website
- www.smartcompany.com.au
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
Raised a A$65m Series A led by Airtree Ventures, announced 17 June 2026, with Plural, Left Lane Capital, b2venture and cricketer Pat Cummins participating. It came less than twelve months after a US$10m (A$15m) seed led by Left Lane Capital reported 24 July 2025, when the company cited a waitlist in the tens of thousands and planned international expansion (SmartCompany, 17 June 2026; Longevity.Technology, 24 July 2025).
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Australian startup funding June 2026: Everlab raises $65 million · SmartCompany
- Australian longevity clinic lands $10m for international expansion · Longevity.Technology
Every entity profile on variis is sourced. Not investment advice.